The Science Journal of the Lander College of Arts and Sciences
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. Nootropics, a class of cognitive-enhancing compounds, have recently emerged as potential therapeutic agents for mitigating the cognitive impairments associated with AD. This paper reviews the current evidence regarding the efficacy (or lack thereof) of different treatments used in the past for treating Alzheimer’s, including cholinesterase inhibitors and anti-Aβ antibodies. The findings are compared to those using various nootropics, including natural supplements and synthetic compounds, in modulating neurobiological pathways relevant to AD pathology. Mechanisms of action such as neuroprotection, antioxidant activity, acetylcholine modulation, and anti-inflammatory effects are explored. Preclinical studies demonstrate promising results, showing improved synaptic plasticity and neuronal survival, while clinical trials report mixed but encouraging outcomes in cognitive performance, particularly in early-stage AD patients. Despite this potential, limitations such as small sample sizes, inconsistent dosing regimens, and limited long-term data impede definitive conclusions. Further rigorous randomized controlled trials are necessary to establish the safety, efficacy, and mechanisms of nootropics in Alzheimer’s disease treatment. This review highlights the need for a multidisciplinary approach to fully understand the therapeutic value of nootropics in addressing the cognitive deficits of Alzheimer’s disease.
Recommended Citation
Ben Berkowitz. (2025). Mind Over Matter: Do Nootropics Hold the Key to Fighting Alzheimer’s?. The Science Journal of the Lander College of Arts and Sciences, 18(2), 38-43. Retrieved from https://touroscholar.touro.edu/sjlcas/vol18/iss2/5
